Work Here?
Work Here?
Work Here?
Global Blood Therapeutics focuses on developing treatments for sickle cell disease (SCD), a genetic blood disorder that affects hemoglobin in red blood cells. Their main product, Oxbryta (voxelotor), is an FDA-approved treatment for SCD patients aged 4 and older. The company conducts extensive research, clinical trials, and seeks regulatory approvals to introduce new therapies. Unlike many competitors, GBT emphasizes community advocacy and aims to transform how SCD is treated. Their goal is to improve the lives of those affected by SCD through effective and innovative treatment options.
Company Stage
Acquired
Employees
501-1,000
Industries
Biotechnology, Healthcare
Total Funding
$86.3M
Headquarters
San Francisco, California
Founded
2011
Help us improve and share your feedback! Did you find this helpful?
Find jobs on Simplify and start your career today